Current management of lesions associated with an increased risk of breast cancer
- 27 January 2015
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Clinical Oncology
- Vol. 12 (4), 227-238
- https://doi.org/10.1038/nrclinonc.2015.8
Abstract
High-risk breast lesions, which comprise benign lesions and in situ carcinomas (lobular carcinoma in situ and ductal carcinoma in situ), are clinically, morphologically, and biologically heterogeneous and are associated with an increased risk of invasive breast cancer development, albeit to varying degrees. Recognition and proactive management of such lesions can help to prevent progression to invasive disease, and might, therefore, reduce breast cancer incidence, morbidity, and mortality. However, this opportunity comes with the possibility of overdiagnosis and overtreatment, necessitating risk-based intervention. Notably, despite the progress in defining the molecular changes associated with carcinogenesis, alterations identifying the individuals with high-risk lesions that will progress to invasive carcinoma remain to be identified. Thus, until reproducible clinicopathological or molecular features predicting an individual's risk of breast cancer are found, management strategies must be defined by population-level risks as determined by models such as the Gail or IBIS models, as well as patient attitudes toward the risks and benefits of interventions. Herein, we review the contemporary approaches to diagnosis and management of high-risk breast lesions. Progress in this area will ultimately be dependent on the ability to individualize risk prediction through better definition of the key drivers in the carcinogenic process.Keywords
This publication has 93 references indexed in Scilit:
- Progression from ductal carcinoma in situ to invasive breast cancer: RevisitedMolecular Oncology, 2013
- Blurry Boundaries: Do Epithelial Borderline Lesions of the Breast and Ductal Carcinoma In Situ Have Similar Rates of Subsequent Invasive Cancer?Annals of Surgical Oncology, 2012
- Long-Term Follow-up of Lobular Neoplasia (Atypical Lobular Hyperplasia/Lobular Carcinoma In Situ) Diagnosed on Core Needle BiopsyAnnals of Surgical Oncology, 2012
- Recommendations for women with lobular carcinoma in situ (LCIS).2011
- Management of lobular carcinoma in-situ and atypical lobular hyperplasia of the breast–A reviewEuropean Journal of Surgical Oncology, 2011
- Presence of Lobular Carcinoma In Situ Does Not Increase Local Recurrence in Patients Treated with Breast-Conserving TherapyAnnals of Surgical Oncology, 2008
- Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 StudyJNCI Journal of the National Cancer Institute, 2005
- Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort studyThe Lancet, 2003
- Long-term follow-up of in situ carcinoma of the breast.1994
- Lobular Carcinoma In Situ of the Female BreastThe American Journal of Surgical Pathology, 1993